Using therapeutic drug monitoring to treat KPC-producing klebsiella pneumoniae central nervous system infection with ceftazidime/avibactam

Mohamad Yasmin, Jennifer Hanrahan, Steven Marshall, Thomas P. Lodise, Liang Chen, Federico Perez, Barry Kreiswirth, Robert A. Bonomo

Research output: Contribution to journalArticlepeer-review

3 Scopus citations

Abstract

This report describes the treatment of Klebsiella pneumoniae carbapenemase (KPC)-3-producing multidrug-resistant K. pneumoniae with ceftazidime/avibactam (CAZ-AVI) in a patient who developed postneurosurgical meningitis and bacteremia. Therapeutic drug monitoring of cerebrospinal fluid and blood samples demonstrated CAZ-AVI concentration levels 20-fold greater than the minimum inhibitory concentration in the first 60 minutes postinfusion, providing evidence for the utility of CAZ-AVI in treating KPC-Klebsiella pneumoniae central nervous system infections.

Original languageEnglish (US)
JournalOpen Forum Infectious Diseases
Volume7
Issue number9
DOIs
StatePublished - Sep 1 2020
Externally publishedYes

All Science Journal Classification (ASJC) codes

  • Oncology
  • Clinical Neurology

Keywords

  • Antimicrobial resistance
  • CNS infections
  • Ceftazidime/avibactam
  • KPC
  • Therapeutic drug monitoring

Fingerprint Dive into the research topics of 'Using therapeutic drug monitoring to treat KPC-producing klebsiella pneumoniae central nervous system infection with ceftazidime/avibactam'. Together they form a unique fingerprint.

Cite this